微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 29.44% | -3.76% | -7.9% | 115/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 31.97% | -0.05% | 5.62% | 118/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 30.26% | -4.63% | 1.22% | 119/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 29.9% | -8.77% | -2.27% | 118/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 30.59% | -8.4% | -4.35% | 117/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 31.98% | -4.19% | 0.78% | 117/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.73% | -3.93% | -3.17% | 115/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 32.77% | -0.4% | -1.88% | 115/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 33.4% | -0.07% | 0.06% | 112/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 33.38% | -5.85% | 1.05% | 114/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 33.03% | 0.74% | 0.4% | 108/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 32.9% | -2.72% | -1.56% | 113/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 33.42% | -7.46% | -5.73% | 106/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 35.46% | -0.88% | 8.13% | 119/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 32.79% | -5.95% | -3.05% | 104/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 33.82% | -8.01% | -6.35% | 114/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 36.12% | -2.34% | 0.97% | 95/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 35.77% | -13.19% | 2.6% | 114/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 34.86% | -15.04% | -5.18% | 100/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 36.77% | -9.66% | -0.58% | 103/158 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.98% | -11.73% | -10.24% | 85/158 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 41.2% | -2.33% | 0.4% | 96/158 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 41.04% | 6.57% | 0.83% | 74/158 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 40.7% | 6.03% | -2.86% | 79/158 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 41.9% | 17.21% | -0.69% | 72/158 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 42.19% | 33.08% | 9.56% | 88/158 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 38.51% | 40.8% | 0.32% | 76/158 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 38.39% | 64.62% | 7.39% | 76/158 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 35.74% | 72.15% | 12.75% | 76/158 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 31.7% | 63.76% | 15.92% | 94/158 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 27.35% | 41.51% | 17.29% | 82/158 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 23.32% | 24.28% | 12.3% | 95/158 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 20.76% | 18.02% | 7.26% | 82/158 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 19.36% | 6.41% | 0.16% | 107/158 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 19.33% | 14.22% | 3.01% | 78/158 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 18.76% | 15.6% | 6.64% | 86/158 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 17.59% | 3.76% | -3.29% | 76/158 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 18.19% | 12.02% | 7.51% | 97/158 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 16.92% | 24.1% | 4.26% | 74/158 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 16.23% | 22.45% | -4.28% | 79/158 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 16.96% | 42.51% | 4.41% | 70/158 | 43.46% | 舒泰神 | 94.4% | 行业排名> |